Investing

Amarin : AMRN

AMRN

Stock Data

$14.36

$0.10 (0.70%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

DRUG MANUFACTURERS - GENERAL

Amarin Corp is a Dublin-based pharmaceutical company focused on creating treatments for cardiovascular diseases. Its flagship product, VASCEPA, is an omega-3 fatty acid prescription used to lower triglyceride levels in adults with severe hypertriglyceridemia, contributing to heart health. Amarin markets its products mainly through wholesalers and specialty pharmacies, also collaborating with Mochida Pharmaceutical for further development. Originally named Ethical Holdings, Amarin has been advancing heart disease treatment since its inception in 1989.

Latest Activity

AMRNAmarin

Q2 2026

Jul 29, 4:30pm ET

EPS

-$0.02

est -$0.01-$0.01

Revenue

$42M

est $45M-5.3%

Amarin missed on revenue and earnings but the real story is the cost discipline: a completed $70 million restructuring slashed operating expenses 59% year over year, while CEO Aaron Berg signaled the company is working with Barclays to explore shareholder value pathways beyond the struggling U.S. VASCEPA franchise.

ShareRead more

All Amarin Articles

63 Articles

Chris Lange | May 6, 2022 at 10:50 AM EDT

April’s Tight Labor Market Numbers: Analysts Upgrade or Downgrade Coupang, Hanesbrands, United Airlines and More

Friday’s additional top analyst upgrades and downgrades were on Amarin, Ardely, Ball, Coupang, Hanesbrands, United Airlines, Vimeo and more.

Lee Jackson | May 12, 2021 at 8:58 AM EDT

Wednesday’s Top Analyst Upgrades and Downgrades: DraftKings, Dollar General, HPE, Novavax, Rackspace, Unity Software, Weyerhaeuser and More

Wednesday's top analyst upgrades and downgrades included DraftKings, Dollar General, Hewlett Packard Enterprise, Novavax, Rackspace, Unity Software and Weyerhaeuser.

Chris Lange | Aug 4, 2020 at 10:04 AM EDT

Is European Update Overshadowing Amarin’s Lackluster Earnings?

Amarin reported its latest quarterly results on Tuesday morning and gave an update on the most recent developments with its…

247sarah | Jun 16, 2020 at 11:38 AM EDT

Why Some Analysts Remain Bullish on Amarin Stock

Is it time to buy Amarin? The biopharmaceutical company just announced a new study showing its drug Vascepa can significantly…

Paul Ausick | Jun 9, 2020 at 12:36 PM EDT

What Amarin Stock Investors Will Hear at the Annual Meeting

Among the items on the annual shareholders meeting agenda are the usual proposals. The board also has submitted a new…

247sarah | Jun 4, 2020 at 12:10 PM EDT

Amarin Stock Is in a Holding Pattern

Amarin is on hold as generic rivals seek to copy its potential blockbuster Vascepa.

247sarah | Jun 2, 2020 at 12:17 PM EDT

Will New Marketing Push Pump Amarin Stock?

Amarin is going ahead with a big marketing campaign for potential COVID treatment Vascepa after a disruption caused by the…

Paul Ausick | May 29, 2020 at 1:34 PM EDT

How Court Ruling, COVID-19 Use Could Close 2020 Amarin Stock Saga

While Amarin supports research into Vascepa's possible use in treating COVID-19, the financial benefits promise to be greater if Vascepa's…

247sarah | May 27, 2020 at 1:53 PM EDT

Potential COVID-19 Treatment Could Help Amarin Stock

Amarin’s Vascepa treats cardiovascular disease, which is a big risk factor for COVID-19 patients, but is the subject of patent…

Chris Lange | May 22, 2020 at 12:53 PM EDT

Amarin Stock’s Potential Unhampered by Generic Approval

Amarin will trial Vascepa as a COVID-19 treatment and that could more than offset investor concerns about patent litigation.

247sarah | May 19, 2020 at 1:43 PM EDT

Will Amarin Stock’s Fundamentals Outweigh Patent Trial?

Amarin won FDA approval for its Vascepa cardiovascular disease drug in December but the pandemic and patent litigation are weighing…

Chris Lange | May 13, 2020 at 1:48 PM EDT

Huge Sales Growth Brightens Future for Amarin Stock

There are still a lot of questions for Amarin must figure out before it gets back on track. For investors,…

247sarah | May 8, 2020 at 2:02 PM EDT

Why an Appeals Court May Hold Key to Amarin Stock Future

Amarin Corp. PLC (NASDAQ: AMRN) plans to mount a vigorous and speedy appeal of a U.S. District Court ruling that…

Paul Ausick | Apr 28, 2020 at 12:26 PM EDT

Can Amarin Stock Overcome COVID-19 and Legal Headwinds?

Amarin has two big problems. Getting an unfavorable court decision overruled is by far the more important.

Chris Lange | Apr 17, 2020 at 7:30 AM EDT

Is Amarin Stock Doomed After Court Ruling?

Amarin stock was absolutely crushed at the tail end of March, and now the company is dealing with the fallout.…